Parkinson’s disease prevalence, age distribution and staging in Colombia

Orozco, Jorge; Valderrama-Chaparro, Jaime Andrés; Pinilla-Monsalve, Gabriel David; Molina-Echeverry, María Isabel; Pérez, Ana Coca; Ariza-Araujo, Yoseth; Prada, Sergio I.; Takeuchi, Yuri

doi:10.4081/ni.2020.8401

Cited by 33 publications

(33 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PD cases were 53% male and had a mean age of 61.7 years (±12.8 years) and a mean age at onset of 54.1 years (±14.4 years); controls were 33% male and had a mean age of 56.5 years (±14.6 years). Though the sex ratio of PD cases is lower in LARGE‐PD than that of U.S.‐based Hispanic/Latinos, 10 it appears to be concordant with that of other studies in the region 43,44 . Hispanic/Latino populations tend to have a three‐way admixture pattern with contributions from African, European, and Native American ancestry.…”

Section: Resultssupporting

confidence: 82%

Characterizing the Genetic Architecture of Parkinson's Disease in Latinos

Loesch

Horimoto

Heilbron

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

Objective This work was undertaken in order to identify Parkinson's disease (PD) risk variants in a Latino cohort, to describe the overlap in the genetic architecture of PD in Latinos compared to European‐ancestry subjects, and to increase the diversity in PD genome‐wide association (GWAS) data. Methods We genotyped and imputed 1,497 PD cases and controls recruited from nine clinical sites across South America. We performed a GWAS using logistic mixed models; variants with a p‐value <1 × 10−5 were tested in a replication cohort of 1,234 self‐reported Latino PD cases and 439,522 Latino controls from 23andMe, Inc. We also performed an admixture mapping analysis where local ancestry blocks were tested for association with PD status. Results One locus, SNCA, achieved genome‐wide significance (p‐value <5 × 10−8); rs356182 achieved genome‐wide significance in both the discovery and the replication cohorts (discovery, G allele: 1.58 OR, 95% CI 1.35–1.86, p‐value 2.48 × 10−8; 23andMe, G allele: 1.26 OR, 95% CI 1.16–1.37, p‐value 4.55 × 10−8). In our admixture mapping analysis, a locus on chromosome 14, containing the gene STXBP6, achieved significance in a joint test of ancestries and in the Native American single‐ancestry test (p‐value <5 × 10−5). A second locus on chromosome 6, containing the gene RPS6KA2, achieved significance in the African single‐ancestry test (p‐value <5 × 10−5). Interpretation This study demonstrated the importance of the SNCA locus for the etiology of PD in Latinos. By leveraging the demographic history of our cohort via admixture mapping, we identified two potential PD risk loci that merit further study. ANN NEUROL 2021;90:353–365

show abstract

Section: Resultssupporting

confidence: 82%

Characterizing the Genetic Architecture of Parkinson's Disease in Latinos

Loesch

Horimoto

Heilbron

et al. 2021

Annals of Neurology

View full text Add to dashboard Cite

show abstract

“…A systematic review showed that the prevalence of dementia in patients with PD (PDD) ranges from 17.4 to 31.5%, with an average of 24.5%, which is higher than that in our cohort. The prevalence of dementia in our Colombian cohort is 4.9% for all patients and 6.9% for patients aged 65 years and older, which is considerably higher than the prevalence of 5.14% observed in the general Chinese population aged 65 years and older [4,10].…”

Section: Epidemiologycontrasting

confidence: 70%

“…Epidemiological data on PD are highly variable across countries. These differences can be explained by the variability in the diagnostic criteria, changes in population age distribution and the access to health care services, including the opportunity to consult with trained doctors and specialists [3][4][5].…”

Section: Epidemiologymentioning

confidence: 99%

“…Beatriz Munoz Ospina 1 *, Valentina Quintana-Peña 2 , Daniela Alvarez 3,4 , Jaime A. Valderrama 1,4 , Yuri Takeuchi 1 and Jorge L. Orozco 1 1 Fundación Valle del Lili Cali, Colombia 2 Centro de Investigaciones Clínicas, Fundación Valle del Lili Cali, Colombia 3 Grupo de Investigación i2T Cali, Colombia 4 Universidad Icesi Cali, Colombia *Address all correspondence to: beatriz.munoz@fvl.org.co the control of neurological symptoms. Especially with benzodiazepines, anticholinergics/antimuscarinics used in gastrointestinal or bladder disorders, tricyclic antidepressants, or antipsychotic drugs, several observational studies have shown an association between exposure to anticholinergic drugs and the risk of cognitive impairment [97].…”

Section: Author Detailsmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives of Cognitive Impairment and Behavioral Disturbances in Parkinson’s Disease Dementia

Munoz¹,

Quintana-Peña²,

Alvarez³

et al. 2022

Dementia in Parkinson’s Disease - Everything You Need to Know

Self Cite

View full text Add to dashboard Cite

Parkinson’s disease dementia is a critical stage of the disease because that has a negative impact on the quality of life and functional independence in activities daily living. How the cognition progress to dementia is a key to be explored. The cognitive impairment shows two profiles: cortical (memory encoding, visuospatial abilities, and language) and subcortical, with a dysexecutive syndrome that includes deficits in recognition memory, attention processes, and visual perception as well as visual hallucinations and cognitive fluctuations. Behavioral problems such as apathy, anxiety, depression, and impulse control disorders take a significant part in the loss of autonomy and progression of the disease. To detect the risk of Parkinson’s disease dementia development, the integral evaluation of patients in all stages of the disease should consider the interplay of genetic and epigenetic factors, motor subtypes, and non-motor symptoms (NMS) in order to implement different therapeutics and supportive strategies when they are likely to have efficacy.

show abstract

“…Parkinson's disease (PD) is a progressive neurodegenerative disorder associated with motional and cognitive function. It is the second-highest prevalent neurodegenerative disease after Alzheimer's disease [195]. As the count of countries affected by an aging society has been growing, the number of people diagnosed with PD is also growing.…”

Section: Parkinson's Diseasementioning

confidence: 99%

Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

2021

View full text Add to dashboard Cite

Treatment of neurodegenerative diseases or other central nervous system (CNS) disorders has always been a significant challenge. The nature of the blood-brain barrier (BBB) limits the penetration of therapeutic molecules to the brain after oral or parenteral administration, which, in combination with hepatic metabolism and drug elimination and inactivation during its journey in the systemic circulation, decreases the efficacy of the treatment, requires high drug doses and often induces adverse side effects. Nose-to-brain drug delivery allows the direct transport of therapeutic molecules by bypassing the BBB and increases drug concentration in the brain. The present review describes mechanisms of nose-to-brain drug delivery and discusses recent advances in this area with especial emphasis on nanotechnology-based approaches.

show abstract

Parkinson’s disease prevalence, age distribution and staging in Colombia

Cited by 33 publications

References 27 publications

Characterizing the Genetic Architecture of Parkinson's Disease in Latinos

Characterizing the Genetic Architecture of Parkinson's Disease in Latinos

Perspectives of Cognitive Impairment and Behavioral Disturbances in Parkinson’s Disease Dementia

Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier

Contact Info

Product

Resources

About